We previously reported that Canada’s Federal Court of Appeal (FCA) released its judgment in Canada (Attorney General) v Sandoz Canada Inc, 2015 FCA 249, finding that authorized generics were within the jurisdiction of Patented Medicines Prices and Review Board (PMPRB) (see prior article in the E-TIPS® newsletter here). On November 20, 2016, the respondents, ratiopharm (now Teva) and Sandoz filed a motion requesting the FCA to reconsider the judgment.
E-TIPS® ISSUE
Disclaimer: This Newsletter is intended to provide readers with general information on legal developments in the areas of e-commerce, information technology and intellectual property. It is not intended to be a complete statement of the law, nor is it intended to provide legal advice. No person should act or rely upon the information contained in this newsletter without seeking legal advice.
E-TIPS is a registered trade-mark of Deeth Williams Wall LLP.
